论文部分内容阅读
目的:观察胰岛素增敏剂罗格列酮治疗2型糖尿病伴高血压患者,评价其降压作用,探讨其降压机制。方法:32例2型糖尿病患者按血压分组,口服罗格列酮(文迪雅)4~8mg.d-1,共8周,计算胰岛素敏感指数和抵抗指数。结果:罗格列酮分别降低了2组的血压水平,胰岛素敏感指数升高,抵抗指数降低。结论:罗格列酮治疗2型糖尿病伴有高血压的患者的时候,在降低血浆胰岛素水平、改善胰岛素抵抗的同时,能够明显降低血压。
Objective: To observe the effect of insulin-sensitizing agent rosiglitazone on type 2 diabetes mellitus patients with hypertension and evaluate its antihypertensive effect. Methods: 32 patients with type 2 diabetes were divided into two groups according to their blood pressure: oral administration of rosiglitazone (Avandia) 4 ~ 8mg.d-1 for 8 weeks to calculate the insulin sensitivity index and resistance index. Results: Rosiglitazone reduced blood pressure, insulin sensitivity index and resistance index decreased in two groups respectively. Conclusion: Rosiglitazone can significantly lower blood pressure while lowering plasma insulin and improving insulin resistance in patients with type 2 diabetes mellitus and hypertension.